Also in November 2008, NeoStem agreed to acquire a Hong Kong corporation with a series of contracts in place with Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine LLC ("Shandong"). Shandong is a provider of regenerative medical therapies in China and provides a multitude of treatments including cell regenerative therapies.
The closing of the CHBP and Shandong transactions are subject to shareholder approvals and other conditions set forth in the agreements. The acquisitions will add materially to NeoStem's existing business and intellectual property platform and open international access for the Company and its clientele to advanced stem cell technologies for a growing number of conditions.
For more information, please visit: www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results, including the success of the Dr. Giampapa stem cell collection center, the successful closing of the CHBP and Shandong transaction and the realization of the potential strategic benefits of the transactions could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ fro
|SOURCE NeoStem, Inc.|
Copyright©2009 PR Newswire.
All rights reserved